BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 40 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $38,000 | -35.6% | 10,000 | -23.1% | 0.00% | -40.0% |
| Q4 2020 | $59,000 | -73.2% | 13,000 | 0.0% | 0.01% | -77.3% |
| Q3 2020 | $220,000 | +50.7% | 13,000 | 0.0% | 0.02% | +10.0% |
| Q2 2020 | $146,000 | +143.3% | 13,000 | 0.0% | 0.02% | +122.2% |
| Q1 2020 | $60,000 | +7.1% | 13,000 | 0.0% | 0.01% | +28.6% |
| Q4 2019 | $56,000 | +9.8% | 13,000 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $51,000 | -25.0% | 13,000 | -24.9% | 0.01% | -30.0% |
| Q2 2019 | $68,000 | -9.3% | 17,300 | 0.0% | 0.01% | -16.7% |
| Q1 2019 | $75,000 | +63.0% | 17,300 | +33.1% | 0.01% | +33.3% |
| Q4 2018 | $46,000 | +9.5% | 13,000 | +18.2% | 0.01% | 0.0% |
| Q3 2018 | $42,000 | -2.3% | 11,000 | 0.0% | 0.01% | -18.2% |
| Q2 2018 | $43,000 | +48.3% | 11,000 | +22.2% | 0.01% | +37.5% |
| Q1 2018 | $29,000 | -6.5% | 9,000 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $31,000 | – | 9,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 189,935 | $311,494 | 0.08% |
| ABNER HERRMAN & BROCK LLC | 280,000 | $459 | 0.07% |
| Weaver Consulting Group | 65,947 | $108,153 | 0.06% |
| S.C. Financial Services, Inc. | 25,372 | $41,610 | 0.03% |
| JMAC ENTERPRISES LLC | 40,430 | $66,305 | 0.02% |
| Weaver Consulting Group | 53,500 | $10,047 | 0.01% |
| IFP Advisors, Inc | 26,650 | $139 | 0.00% |
| Bangor Savings Bank | 4,000 | $7 | 0.00% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $4,920 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 19,098 | $31,321 | 0.00% |